Health
Molnupiravir (MK-4482/EIDD-2801) Antiviral — Precision Vaccinations – PrecisionVaccinations
Molnupiravir (MK-4482/EIDD-2801) antiviral is indicated to mitigate SARS-CoV-2 infection and block transmission, hence preventing COVID-19 disease.
Molnupiravir (MK-4482/EIDD-2801) Antiviral Description
Molnupiravir (MK-4482/EIDD-2801) is an oral antiviral drug that was originally developed for the treatment of influenza. MK-4482/EIDD-2801 consists of the nucleoside analogue N4-hydroxycytidine (NHC). Molnupiravir has been evaluated against coronaviruses (CoVs) including SARS-1, MERS-CoV, and SARS-CoV-2.
The drug was originally developed at Emory University by the university’s drug innovation company, Drug Innovation Ventures at Emory (DRIVE)….
-
General11 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News20 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General18 hours agoCrowe toasts talkback titan for platforming ‘voiceless’
-
Noosa News12 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial